24/7 Market News Snapshot 30 December, 2024 – Autonomix Medical, Inc. Common Stock (NASDAQ:AMIX)

December 30, 2024

DENVER, Colo., 30 December, 2024 (247marketnews.com) – (NASDAQ:AMIX) are discussed in this article.
Autonomix Medical, Inc. (NASDAQ:AMIX) is witnessing a remarkable surge in pre-market trading, with shares priced at $6.08—an impressive increase of 84.24% from the previous session’s close of $3.30. Trading activity is robust, with a significant volume of 4.62 million shares exchanged, indicating strong investor enthusiasm and confidence in the stock. As the company approaches the market open, trader interest remains elevated, suggesting a potential continued upward trajectory for AMIX.

This exciting momentum comes on the heels of Autonomix securing a new patent—U.S. patent 12,064,256—granted by the United States Patent and Trademark Office (USPTO). The patent, titled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function,” strengthens Autonomix’s already extensive intellectual property portfolio, which now totals over 120 patents, including 80 issued and more than 40 pending. The newly acquired patent enhances the company’s capabilities in advancing its pioneering technology aimed at treating conditions related to the nervous system.

Autonomix’s latest innovations focus on targeted nerve ablation intended to alleviate cancer-related pain, particularly in the context of pancreatic cancer. Prior preclinical studies have shown statistically significant reductions in both tumor mass and metastases, emphasizing the potential of neuropathway targeting in addressing the complexities of this challenging disease.

Brad Hauser, CEO of Autonomix, expressed the team’s dedication to developing transformative therapeutic approaches, highlighting the importance of patent protection in the journey to redefine treatment standards. As the company prepares for further clinical exploration, it remains committed to enhancing patient care through innovative solutions, aiming to slow the progression of pancreatic cancer while improving the quality of life for affected individuals. With its extensive patent portfolio and ambitious clinical plans, Autonomix Medical stands ready to make a significant impact in the medical device landscape.

Related news for (AMIX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.